Upadacitinib — Drug Intelligence | 34 EU Trials

Filter these 34 trials by condition, phase, country and more.

Open in Search →

34 Registered trials

17 Recruiting

14 Completed trials

11 Sponsors

25 Countries

Phase III

Phase III/IV

Phase IV

Phase III: 17 Phase II: 3 Phase III/IV: 5 Phase IV: 8 Phase I (Other): 1

Oversight events:

1 serious breach 3 corrective measures across 4 trials

View oversight register →

Indications tested

Dermatitis atopic 5 Crohn's disease 3 Rheumatoid arthritis 2 Colitis ulcerative 2 Axial spondyloarthritis 2 Juvenile idiopathic arthritis 2 Immune-mediated myositis 1 Alopecia areata 1 Giant cell arteritis 1 Psoriatic arthropathy 1 Polymyositis 1 Dermatomyositis 1

Sponsors using this IMP

AbbVie Deutschland GmbH & Co. KG 20 Centre Hospitalier Universitaire De Nantes 3 Care Arthritis Ltd. 2 Universitaetsklinikum Heidelberg AöR 2 Alimentiv Inc. 1 Dr. Douglas D. Fraser 1 Hospital Universitario La Paz 1 Les Hopitaux Universitaires De Strasbourg 1 Medical University Of Vienna 1 Sint Maartenskliniek Stichting 1 Takeda Development Center Americas Inc. 1

All trials — page 2

34 total

Evaluation of Upadacitinib in Combination with Topical Corticosteroids in Adolescent and Adult Patients with Moderate to Severe Atopic Derma… Ended

2022-502937-24-00 Phase III 18 countries Abbvie Deutschland GmbH & Co. KG
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohn's Disease who Comple… Ended

2023-504951-29-00 Phase III 19 countries AbbVie Deutschland GmbH & Co. KG
Long Term Safety and Efficacy of ABT-494 in Subjects with Ulcerative Colitis. Ended

2023-505699-31-00 Phase III 20 countries AbbVie Deutschland GmbH & Co. KG
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects with Rheumatoid Arthritis who are on a Stable Dose of Meth… Ended

2022-501017-31-00 Phase III 17 countries Abbvie Deutschland GmbH & Co. KG
This is a study to evaluate dose-flexibility of Upadacitinib in Adult Subjects with Moderate to Severe Atopic Dermatitis Ended

2023-504869-23-00 Phase III/IV 10 countries AbbVie Deutschland GmbH & Co. KG
U3P study - Upadacitinib in Psoriatic Arthritis Pain Processing Ended

2024-512669-15-00 Phase IV 1 country Universitaetsklinikum Erlangen AöR
A safety and efficacy study of ABT-494 in subjects with Giant Cell Arteritis. Ended

2023-505476-29-00 Phase III 10 countries AbbVie Deutschland GmbH & Co. KG
Evaluation of Upadacitinib in Adolescent and Adult Patients with Moderate to Severe Atopic Dermatitis (Eczema) – Measure Up 2 Ended

2022-502936-38-00 Phase III 15 countries Abbvie Deutschland GmbH & Co. KG
Evaluation of Upadacitinib in Adolescent and Adult Patients with Moderate to Severe Atopic Dermatitis (Eczema)– Measure Up 1 Ended

2022-502938-30-00 Phase III 9 countries Abbvie Deutschland GmbH & Co. KG
A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants Wi… Ended

2024-510727-19-00 Phase II 6 countries AbbVie Deutschland GmbH & Co. KG

Showing 25–34 of 34 trials

← All drugs A–Z